MedTrace Logo

Ketamine in OCD: Efficacy and Effects on Stress and Cognition

NCT05577585 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-06-25

No results posted yet for this study

Summary

The main goal of this trial is to demonstrate therapeutic efficacy of low dose ketamine in patients with OCD. We expect that ketamine will alleviate symptoms in the hours following application, but also - if effective - that the anti-OCD effects might last for several days after a single infusion.

Conditions

  • Obsessive-Compulsive Disorder
  • Psychiatric Disorder

Interventions

DRUG

Ketamine 50 MG/ML Blinded

See also Arm description

DRUG

Midazolam

See also Arm description

DRUG

Ketamine 50 MG/ML Open Label

Open Label Follow Up (up to 8 Infusions)

OTHER

Treatment as Usual (TAU)

Treatment as Usual may include psychotherapy, pharmacotherapy, physiotherapy, ergotherapy, or a combination of these-at the discretion of the treating physician, independently of the study.

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Christoph Kraus, MD PhD · Medical University of Vienna, Department of Psychiatry and Psychotherapy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05577585 on ClinicalTrials.gov